Scholarlink

Background <p>Preeclampsia (PE) is a hypertensive disorder in pregnancy involving multiple organ systems, primarily due to impaired placental development during the first trimester. Reduced Placenta Growth Factor (PlGF) and elevated Glycosylated Fibronectin (GlyFn) levels reflect these pathological changes. Combining these biomarkers into a ratio may enhance PE prediction in high-risk pregnancies.</p> Objective <p>To evaluate the GlyFn/PlGF ratio measured at 20–28 weeks of gestation as a predictor of preeclampsia in high-risk pregnancies across four hospitals in West Java, Indonesia, from April–October 2024.</p> Methods <p>This prospective cohort study involved 54 high-risk pregnant women. The GlyFn/PlGF ratio was analyzed at 20–28 weeks to assess predictive accuracy for PE.</p> Results <p>Significant differences were noted between PE and non-PE groups in pre-pregnancy weight (65.54 ± 12.69 vs. 58.53 ± 7.85&#xa0;kg), BMI (45.52 ± 53.73 vs. 19.84 ± 2.97), and systolic blood pressure (153.50 ± 19.42 vs. 100.80 ± 15.38 mmHg) (<i>P</i> &gt; 0.05). Risk factors such as prior PE (<i>P</i> = 0.01), diabetes mellitus (<i>P</i> = 0.03), and gestational hypertension (<i>P</i> = 0.02) were more frequent in the PE group. A GlyFn cutoff of 34.31 ng/mL showed a 2.5-fold increased PE risk (sensitivity: 83.33%, specificity: 66.67%, AUC: 0.8071). A PlGF cutoff of 26.72 pg/mL was associated with a 6.8-fold increased risk (sensitivity: 72.22%, specificity: 97.22%, AUC: 0.9147). The GlyFn/PlGF ratio cutoff of 1.288 indicated a 28-fold higher PE risk (sensitivity: 77.78%, specificity: 97.37%, AUC: 0.9244).</p> Conclusion <p>The GlyFn/PlGF ratio outperforms individual biomarkers in predicting preeclampsia in high-risk pregnancies, offering a valuable tool for early risk identification and timely intervention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictive value of Glycosylated Fibronectin (GlyFn)/Placenta Growth Factor (PlGF) ratio for high-risk pregnancies: a cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月17日

查看全文
  • Wahyudi Wirawan,
  • Sofie Rifayani Krisnadi,
  • Anita Deborah Anwar,
  • Annisa Dewi Nugrahani

摘要

Background

Preeclampsia (PE) is a hypertensive disorder in pregnancy involving multiple organ systems, primarily due to impaired placental development during the first trimester. Reduced Placenta Growth Factor (PlGF) and elevated Glycosylated Fibronectin (GlyFn) levels reflect these pathological changes. Combining these biomarkers into a ratio may enhance PE prediction in high-risk pregnancies.

Objective

To evaluate the GlyFn/PlGF ratio measured at 20–28 weeks of gestation as a predictor of preeclampsia in high-risk pregnancies across four hospitals in West Java, Indonesia, from April–October 2024.

Methods

This prospective cohort study involved 54 high-risk pregnant women. The GlyFn/PlGF ratio was analyzed at 20–28 weeks to assess predictive accuracy for PE.

Results

Significant differences were noted between PE and non-PE groups in pre-pregnancy weight (65.54 ± 12.69 vs. 58.53 ± 7.85 kg), BMI (45.52 ± 53.73 vs. 19.84 ± 2.97), and systolic blood pressure (153.50 ± 19.42 vs. 100.80 ± 15.38 mmHg) (P > 0.05). Risk factors such as prior PE (P = 0.01), diabetes mellitus (P = 0.03), and gestational hypertension (P = 0.02) were more frequent in the PE group. A GlyFn cutoff of 34.31 ng/mL showed a 2.5-fold increased PE risk (sensitivity: 83.33%, specificity: 66.67%, AUC: 0.8071). A PlGF cutoff of 26.72 pg/mL was associated with a 6.8-fold increased risk (sensitivity: 72.22%, specificity: 97.22%, AUC: 0.9147). The GlyFn/PlGF ratio cutoff of 1.288 indicated a 28-fold higher PE risk (sensitivity: 77.78%, specificity: 97.37%, AUC: 0.9244).

Conclusion

The GlyFn/PlGF ratio outperforms individual biomarkers in predicting preeclampsia in high-risk pregnancies, offering a valuable tool for early risk identification and timely intervention.